Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Did you know Amouranth was once domestic violence victim? Has Twitch queen moved on?
Google Chrome will use generative AI to summarize articles
Every Amazon device for kids is down to its lowest price ever for Prime Day
Biden to nominate Democrat for key seat on US telecom regulator
Use Your FC 24 Founders Evolution On These Players Only
Adam Warlock in the new Guardians of the Galaxy movie has become an instant meme
Intel Is the First Major Chip Maker to Report Earnings. Wall Street Is Focused on This Stat.
British Columbia wildfires intensify, doubling evacuations to over 35,000